Clinical Trial Update: UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 Japanese UNITY 3 trial evaluating daclatasvir/asunaprevir/BMS-791325 in genotype 1 chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daklinza (Daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED